Time to initiation of care for human immunodeficiency virus (HIV) infection by site of diagnosis in persons diagnosed as having HIV (non-AIDS) by positive Western blot test in New York City, 2003. STD indicates sexually transmitted disease; TB, tuberculosis.
Torian LV, Wiewel EW, Liu K, Sackoff JE, Frieden TR. Risk Factors for Delayed Initiation of Medical Care After Diagnosis of Human Immunodeficiency Virus. Arch Intern Med. 2008;168(11):1181-1187. doi:10.1001/archinte.168.11.1181
Copyright 2008 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2008
The full benefit of timely diagnosis of human immunodeficiency virus (HIV) infection is realized only if there is timely initiation of medical care. We used routine surveillance data to measure time to initiation of care in New York City residents diagnosed as having HIV by positive Western blot test in 2003.
The time between the first positive Western blot test and the first reported viral load and/or CD4 cell count or percentage was used to indicate the interval from initial diagnosis of HIV (non-AIDS) to first HIV-related medical care visit. Using Cox proportional hazards regression, we identified variables associated with delayed initiation of care and calculated their hazard ratios (HRs).
Of 1928 patients, 1228 (63.7%) initiated care within 3 months of diagnosis, 369 (19.1%) initiated care later than 3 months, and 331 (17.2%) never initiated care. Predictors of delayed care were as follows: diagnosis at a community testing site (HR, 1.9; 95% confidence interval [CI], 1.5-2.3), the city correctional system (HR, 1.6; 95% CI, 1.2-2.0), or Department of Health sexually transmitted diseases or tuberculosis clinics (HR, 1.3; 95% CI, 1.1-1.6) vs a site with colocated primary medical care; nonwhite race/ethnicity (HR, 1.8; 95% CI, 1.5-2.0); injection drug use (HR, 1.3; 95% CI, 1.1-1.5); and location of birth outside the United States (HR, 1.1; 95% CI, 1.0-1.2).
A total of 1597 persons (82.8%) diagnosed as having HIV in 2003 ever initiated care, most within 3 months of diagnosis. Initiation of care was most timely when diagnosis occurred at a testing site that offered colocated medical care. Improving referrals by nonmedical sites is critical. However, because most diagnoses occur in medical sites, improving linkage in these sites will have the greatest effect on timely initiation of care.
Because acute human immunodeficiency virus (HIV) infection is brief, self-limited, and challenging to diagnose, most HIV-positive persons are diagnosed 1 or more years into the chronic disease phase, and many are not diagnosed as having HIV until their infections have already progressed to AIDS.1- 5 Expansion of testing opportunities and replacement of risk-based testing with routine testing can reduce delayed diagnosis.5 However, the full personal and public health value of timely diagnosis can be realized only when it is followed by timely initiation of medical care.6 Delayed care translates into lost opportunities for prevention, virologic and immunologic monitoring, timely initiation of antiretroviral therapy, and management of HIV and related health and social issues.7
The Centers for Disease Control and Prevention and the Department of Health and Human Services recommend that HIV-related medical care with regular monitoring of viral load (VL) and CD4 cell count be initiated as early as possible after diagnosis,8- 10 and the New York City Department of Health and Mental Hygiene has established 3 months as the benchmark for initiation of care. New York City, a high-morbidity area with more than 6000 new HIV and AIDS diagnoses annually and a cumulative total of more than 200 000 cases, has a comprehensive named HIV reporting system that permits the use of routinely reported laboratory test results to measure time from diagnosis to care and subsequent use of care. We used routine population-based surveillance data to calculate time to first visit and to evaluate risk factors for delayed care among New York City residents newly diagnosed as having HIV (non-AIDS) by positive Western blot test in 2003.
New York State requires named reporting of all diagnoses of HIV and AIDS, all HIV-related illness, all positive Western blot tests for HIV antibody, all VL and CD4 cell count values, and all HIV genotypes.11 The New York City HIV/AIDS Reporting System (HARS) is a population-based registry that, since 1981, has been continuously updated with new, deduplicated diagnoses and laboratory results. All incoming provider and laboratory reports that do not match an existing registry record initiate a field investigation with medical record review to confirm the case, date, and disposition of diagnosis and collect all other data required for surveillance and partner notification. HARS also obtains data through regular matches with other disease registries: the New York City Death Registry, the National Death Index, and the Social Security Death Master File. All data used in this analysis were drawn from HARS as of December 31, 2006.
This analysis included all persons reported to HARS who had an initial HIV (non-AIDS) diagnosis by positive Western blot in 2003, diagnosed by a known provider, and who resided in New York City at diagnosis (N = 1928). We did not include diagnoses of concurrent HIV/AIDS or AIDS because New York State law requires that a physician make the diagnosis of AIDS by either the immunologic criterion (CD4 cell count <200/μL) or the diagnosis of an AIDS-defining condition. All patients with AIDS are by definition in medical care.
A total of 3373 persons were diagnosed as having HIV (non-AIDS) in 2003 and were reported to HARS. Our ability to calculate the time between diagnosis and first laboratory test required that both events be precisely defined and dated and that there be a single consistent, transparent definition of new HIV diagnosis. Thus, we required that patients’ conditions be diagnosed by positive Western blot test on blood or oral fluid drawn on a valid date in 2003 and reported by the testing laboratory to the state health department. A total of 917 diagnoses had no diagnostic Western blot in HARS. These presumptive physician diagnoses were eliminated from the analysis because they did not meet the criterion of a dated laboratory-confirmed diagnostic test, allowing calculation of the interval from initial diagnosis to first medical care, and because experience with medical record review in such cases indicates that although many cases are not new in 2003, standardized coding conventions require that we ascribe them to the year of report in the absence of other confirmatory data. Moreover, because all such diagnoses are made by physicians, the patient is by definition already in care. Other reasons for the elimination of cases included undergoing a laboratory test before initial HIV diagnosis (n = 6), reference laboratory (not the true test site) or missing provider for the initial diagnostic test (n = 297), and non–New York City residence at diagnosis (n = 225).
We used the date of the first reported VL or CD4 cell count or percentage as the date of initiation of care. Both tests indicate care because they must be ordered by a physician. The interval from diagnosis to care was a continuous variable measured in days between the first positive Western blot test and first VL and/or CD4 cell count. We defined a high-poverty zip code as one in which the income of 20% or more of the population was below the federal poverty level.12 Persons were classified by country of birth as born in the United States, in a US dependency, or in a foreign country. Foreign-born persons were categorized by region. Country of birth was also dichotomized as United States or outside the Unites States (includes US dependencies, foreign countries, and unknown).
We calculated the median VL and proportion of patients with a CD4 cell count less than 350/μL and/or a VL greater than 100 000 copies per milliliter8 at first visit. In HARS, the first reported CD4 cell count coincides with our dependent variable; thus, there is no true baseline CD4 cell count (CD4 cell count at diagnosis).
The population analyzed was compared with total 2003 HIV (non-AIDS) diagnoses in HARS to ascertain whether the elimination criteria resulted in significant differences. Standard bivariate methods were used to identify associations between candidate predictor variables and the dependent variable as divided into timely initiation (≤3 months), delayed initiation (>3 months), and never initiated care (Table 1). We also calculated the proportion of persons who initiated care who had a second visit.
We then conducted time-to-event analyses using months between diagnosis and first care (first VL and/or CD4 cell count report) as the dependent variable. Patients contributed observation time from the date of initial diagnosis by positive Western blot to the date of first care or were right censored at death, loss to follow-up via transfer to another jurisdiction, or the end of the analysis period. The Kaplan-Meier product-limit method was used to estimate the cumulative proportion initiating care by month after diagnosis, stratified by site of diagnosis. The log-rank test was used to determine whether the distribution of event times and the proportion of censored observations were equal across the 4 strata. Multivariate Cox proportional hazards regression was used to identify the factors associated with time to initiation of care and to calculate their hazard ratios (HRs). Variables with P < .05 in the bivariate cross-tabulations were eligible for inclusion in the Cox model. SAS statistical software, version 9.1 (SAS Institute, Inc, Cary, North Carolina), was used to conduct the analysis.
The population analyzed mirrored all 2003 HIV (non-AIDS) diagnoses in HARS with respect to risk factor, sex, race, place of birth, and median age at diagnosis but contained significantly more persons living in high-poverty zip codes (63.5% vs 58.1%; P < .001).
Of the 1928 patients, 1597 (82.8%) newly diagnosed as having HIV had initiated care by the end of follow-up (Table 1), 1228 (63.7%) within 3 months and 369 (19.1%) after 3 months. Thus, 76.9% of persons ever initiating care did so within 3 months. No laboratory evidence of HIV-related care was available for 331 persons (17.2%) newly diagnosed as having HIV in 2003. Of those initiating care, 91.1% had at least 1 additional visit during follow-up.
Time to initiation of care was predicted by a combination of individual characteristics and 1 institutional variable (site of initial diagnosis). Significantly fewer injection drug users as opposed to persons with all other risks had initiated care within 3 months (50.6% vs 65.0%; P < .001); similar differences were found for nonwhite persons vs those of white race/ethnicity, persons in high-poverty zip codes vs persons in nonpoverty zip codes, and persons born in foreign countries, in US dependencies, or in an unknown birthplace (62.3%) vs persons born in the United States (65.7%).
Persons whose infections were diagnosed in community testing sites, city jails, and Department of Health sexually transmitted disease (STD) and tuberculosis (TB) clinics without colocated primary medical care were significantly less likely than persons whose infections were diagnosed at sites that also offered primary medical care to have initiated care within 3 months (53.2% vs 66.5%) (Table 2). Significant differences were found in time to care within the nonmedical sites: 59.4% of patients whose infections were diagnosed at Department of Health STD and TB clinics initiated care within 3 months, whereas less than half (49.4% and 48.0%, respectively) of those whose infections were diagnosed in the New York City correctional system and community testing sites did so. Persons whose infections were initially diagnosed in jail and who had at least 1 HIV-related visit were also significantly less likely to have a second visit than persons whose infections were initially diagnosed in all other settings (73.7% vs 92.0%; P < .001).
Among medical sites, persons whose infections were diagnosed in 1 of New York City's 32 designated AIDS centers (DACs) (medical centers that offer multispecialty integrated HIV primary care, clinical trials, and support services) were promptly linked to care in approximately the same proportions as those whose infections were diagnosed at non-DAC medical sites (Table 2). Residents of high-poverty zip codes had more timely linkage to care if their infections were initially diagnosed at a DAC than a non-DAC.
Median VL at first visit was lower in persons who initiated care within 3 months vs those who initiated care at more than 3 months; however, the proportion eligible for highly active antiretroviral therapy8 at first visit was approximately equivalent. Both initiation of care and CD4 cell count are time dependent and are possibly interactive events that are coincident in HARS. We did not observe differences in the proportion with a CD4 cell count of less than 350/μL and/or a VL of greater than 100 000 copies per milliliter across diagnostic sites; however, these values were reported at first visit, not at diagnosis, and they cannot by definition be reported for persons never initiating care. Thus, we could not explore the relationship between clinical symptoms and selection of diagnostic site or time to initiation of care.
The Kaplan-Meier survival curve graphs the distribution of time to care by site of diagnosis (Figure). It illustrates the advantage of having an HIV infection diagnosed at a site that offers primary medical care, the early appearance of this advantage, and its persistence over time. Forty-one patients were censored because they died (n = 21) or moved out of New York City (n = 20) before initiating care or reaching the end of follow-up. The proportion of censored observations was equal across the 4 diagnostic provider strata.
Using a site with colocated medical care as the referent, the Cox proportional hazards regression analysis (Table 3) found that diagnosis at a community testing site conferred a 90% increase in the probability of delayed initiation of care per month during the 36- to 47-month follow-up (HR, 1.9; 95% confidence interval [CI], 1.5-2.3), whereas diagnosis in jail conferred a 60% increase (HR, 1.6; 95% CI, 1.2-2.0) and diagnosis at public STD and TB clinics conferred a 30% increase in the probability of delayed care (HR, 1.3; 95% CI, 1.1-1.6). Three individual factors predicted delayed care: nonwhite race (HR, 1.8; 95% CI, 1.5-2.0), injection drug use as the transmission risk (HR, 1.3; 95% CI, 1.1-1.5), and birth outside the United States (HR, 1.1; 95% CI, 1.0-1.2).
Three hundred thirty-one persons (17.2%) initially diagnosed as having HIV (non-AIDS) in 2003 had no laboratory evidence of medical care by December 31, 2006. Site of initial diagnosis was the most important risk for this outcome. Diagnosis at a community testing site (adjusted odds ratio [AOR], 3.3; 95% CI, 2.3-4.8), jail (AOR, 2.4; 95% CI, 1.4-4.1), or city clinic (AOR, 1.6; 95% CI, 1.1-2.3) was the strongest predictor of failure to initiate care, followed by nonwhite race (AOR, 2.5; 95% CI, 1.6-3.8) and birth outside the United States (AOR, 1.3; 95% CI, 1.0-1.7).
Initial HIV diagnosis at a site without colocated medical care, nonwhite race/ethnicity, injection drug use, and birth outside the United States predicted delayed initiation of care. Extensive literature13- 20 has associated these and related factors (many not measured by HIV/AIDS surveillance) with reduced health care utilization and health disparities nationwide and in New York City.
Medical providers who serve high-risk communities must, therefore, not only expand routine HIV testing but also ensure that it is coupled with proactive linkage to care. Large facilities have infrastructure specifically intended to mitigate individual barriers by facilitating applications for enabling factors21,22 (eg, entitlements, drug treatment, case management, housing, transportation, nutrition, and child care). Referrals will be smoother if linkage occurs within the same administrative entity and/or under the same roof. In the best of circumstances, posttest counselors can personally escort persons who have new positive test results to the on-site HIV clinic, introduce them to clinic personnel, and make the first appointment, perhaps even on the same day. Most of our patients had their infections diagnosed by medical providers. Although these sites performed significantly better did than nonmedical sites, providers at these sites diagnosed the infections of most patients who did not make a timely transition to care. Thus, improvements in their services will have the greatest overall effect on initiation of care in the city. The Department of Health recently deployed experienced staff to New York City's 10 largest reporting hospitals to facilitate initiation of care. However, because of the size, heterogeneity, and geographic distribution of the epidemic, the Department of Health relies heavily on the city's more than 800 institutional and more than 2400 individual diagnostic providers to assist their patients who have new positive test results to make the transition.
Public clinics and community-based organizations play an important role in reaching out to persons not well served by traditional health care institutions and providing supportive environments to those who might not otherwise undergo testing. Jails serve high-risk populations for whom a new diagnosis of HIV may be only 1 of many problems. As our data indicate, arranging postrelease or posttest care and establishing bridges to medical care can be formidable challenges for these sites. However, as testing technology changes and testing expands to more nonmedical settings, including community outreach events and home-based testing, these links will become increasingly important. Our finding that most patients ever presenting for care did so within 3 months suggests that there is a brief “best” window of opportunity after diagnosis. All diagnostic providers should take full advantage of it by creating the best linkage systems possible.
This analysis is subject to limitations that may underestimate the proportion of patients who initiate care. First, before June 1, 2005, undetectable VLs and CD4 cell counts higher than 500/μL were not reported. We presumed that all patients newly diagnosed as having HIV were antiretroviral naïve and would have had a detectable VL on their first primary care visit23- 27 or that our routine medical record review would obtain any VL and CD4 cell count results not reported by laboratories. Standard commercial assays may not be sensitive enough to detect the low levels of viral replication occurring in long-term nonprogressors during latent infection.28- 30 However, these cases are thought to be rare, and some of their VLs may have been measured and reported before reaching set point.
Country of birth outside the United States is documented for 23% of patients newly diagnosed as having HIV in New York City.31 One-quarter of foreign-born persons were born in regions where non-B subtypes predominate. The VLs of persons with non-B and recombinant subtypes may be underestimated by assays optimized for subtype B,32 potentially underestimating initiation of care in 43% to 78%33,34 of persons who acquired HIV in their home country, during travel, or from persons infected with variant subtypes. Some VL assays more accurately quantitate non-B subtype VLs than others,35 but because HARS does not contain data on the VL assay used by the reporting laboratory, we cannot estimate the proportion misclassified as not initiating care for this reason.
Although we restricted our analysis to persons who were residents of New York City at diagnosis, some patients may have relocated after diagnosis and received medical care in another reporting jurisdiction. Patients who moved out of New York City would be officially transferred to their new jurisdiction (and, thus, lost to follow-up) under the Centers for Disease Control and Prevention's Routine Interstate Duplicate Review protocol only at the time of progression to AIDS (ie, we would not know that they were no longer city residents until they were diagnosed as having AIDS).
Finally, laboratory reporting indicates testing but does not provide any insight into the quality or characteristics of the care. Thus, it is possible that some patients' first laboratory report represented a visit to the emergency department rather than a medical provider with whom there would be an opportunity to establish an ongoing primary care relationship.
The past 2 decades have seen the steady transformation of HIV/AIDS from an almost inevitably fatal disease to a chronic manageable condition. The value of early diagnosis and timely initiation of primary care grows with each passing year as new options in diagnosis, antiretroviral therapy, and medical management become available. Timely diagnosis is the essential first step,36,37 but it must be followed by timely initiation of care.
This report shows the size and nature of the challenge of linking persons with a new positive HIV diagnosis to care in a high-morbidity urban environment. New York City offers many settings for HIV diagnosis and expert care and has an extensive institutional support system for persons with HIV. The 32 DACs are distributed throughout the 5 boroughs and are accessible 24 hours a day by what is arguably the best public transportation system in the United States. Medical and prescription drug benefits are designed to ensure that no person goes without care or highly active antiretroviral therapy because of lack of resources. Case management, housing, and nutritional benefits are available. The DACs and large medical facilities have the administrative capacity to reduce many traditional barriers to care by arranging entitlements and ensuring access to support services; most private physicians who treat patients with HIV/AIDS have institutional relationships with hospitals that offer these services.
Despite this, more than one-third of our patients were not promptly linked to care. As advances in therapy extend length and quality of life for persons with HIV and AIDS, public health authorities, their community partners, and primary care physicians must proactively identify and assist those at risk for delayed care so that all HIV-infected persons, regardless of their individual risk factors and resources, can take prompt advantage of the increasingly sophisticated therapeutic options available to them.
Correspondence: Lucia V. Torian, PhD, HIV/AIDS Epidemiology and Field Services Program, Bureau of HIV/AIDS Prevention and Control, New York City Department of Health and Mental Hygiene, 346 Broadway, Room 701, CN 44, New York, NY 10013.
Accepted for Publication: December 17, 2007.
Author Contributions:Study concept and design: Torian, Wiewel, and Frieden. Acquisition of data: Torian, Wiewel, and Sackoff. Analysis and interpretation of data: Torian, Wiewel, Liu, and Sackoff. Drafting of the manuscript: Torian. Critical revision of the manuscript for important intellectual content: Torian, Wiewel, Liu, Sackoff, and Frieden. Statistical analysis: Torian, Wiewel, and Liu. Obtained funding: Torian and Sackoff. Administrative, technical, and material support: Torian, Sackoff, and Frieden. Study supervision: Torian.
Financial Disclosure: None reported.
Funding/Support: This study was supported in part by cooperative agreement U62/CCU223595-03-1 with the Centers for Disease Control and Prevention.
Previous Presentation: This study was presented in part as an abstract at the XVI International AIDS Conference; August 16, 2006; Toronto, Ontario, Canada.